Tenderwize
Retour à la recherche

Infliximab medicinal products (injection solution)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2027 · 367 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Infliximab (ATC: L04AB02 - in der Darreichungsform Injektionslösung)

58/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

58 / 100

Complexité

42 / 100

Facteurs de risque

The structured data says electronic submission is not allowed, while the XML notice says contract documents may be sent...

The structured deadline in the notice and the XML timestamps are not fully aligned (deadline date versus occurrence tim...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products containing infliximab (ATC L04AB02) in injection solution form.
  • Open-house access model with uniform contract terms and equal access for eligible companies.
Afficher le résumé complet

This is an open-house style notice for non-exclusive discount agreements for infliximab medicinal products (ATC L04AB02, injection solution) in Germany. The contracting buyer is AOK Sachsen-Anhalt. The notice states that any eligible pharmaceutical company may join on the same terms, with no individual negotiations and no exclusivity. The contract can start from 2025-11-01 and ends on 2027-10-31 regardless of start date. No contract value is provided. Procurement documents appear available, but only the XML notice text was provided for analysis.

Risques

The structured data says electronic submission is not allowed, while the XML notice says contract documents may be sent...

The structured deadline in the notice and the XML timestamps are not fully aligned (deadline date versus occurrence tim...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Administrative

  • Interested pharmaceutical companies must request the participation documents and the contract from the contact address.
  • The participation documents must be completed in full and signed.
  • The XML notice indicates submission of contract documents by post is possible and also electronically as PDF with a qualified electronic signature via email to...

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Infliximab medicinal products (injection solution)

Single lot for non-exclusive discount agreements for finished medicinal products containing infliximab (ATC L04AB02) in injection solution form. Open-house model: any eligible pharmaceutical company may conclude or join a contract under identical conditions. No exclusivity and no individual negotiations. Earliest contract start is 2025-11-01; maximum duration is 24 months; contract ends on 2027-10-31 regardless of start date. The notice also says contracts may end early if exclusive tenders are later launched under the applicable rules.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
17 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
612510-2025

Documents (1)

Appels d'offres similaires